Nearly 50 health care and consumer groups, including the AHA, voiced their support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act as it was reintroduced yesterday in the new Congress. “The CREATES Act will help ensure that brand-name pharmaceutical companies cannot take advantage of regulatory rules to forestall the competition that is essential for access and innovation,” the groups said in a letter to the bill’s sponsors, Sens. Chuck Grassley, R-Iowa, Patrick Leahy, D-Vt., Amy Klobuchar, D-Minn., and Mike Lee, R-Utah. “With its enactment, the CREATES Act will save patients and taxpayers $3.9 billion over 10 years, according to the Congressional Budget Office, by allowing lower-priced generic drugs to enter the market earlier. We also recognize and appreciate the commitment from Health and Human Services Secretary Alex Azar and Food and Drug Administration Commissioner Scott Gottlieb, M.D., on this important issue. Both have elevated awareness of brand manufacturer ‘gaming’ of FDA regulatory rules to deny would-be generic competitors the ability to purchase samples of brand-name drugs necessary to conduct the FDA-required testing and bring more affordable medicines to market.”

Related News Articles

Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
Senate Finance Committee Ranking Member Ron Wyden, D-Ore., along with several other Democratic senators, yesterday introduced bills aimed at increasing…
Headline
The AHA and Federation of American Hospitals today urged the U.S. Supreme Court to review a federal appeals court decision that allows False Claims Act…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on legislation to roll back changes to the Affordable Care Act by the Trump…
Headline
The AHA yesterday urged Sens. Bill Cassidy, R-La., and Dick Durbin, D-Ill., not to re-introduce legislation that would establish rehabilitation innovation…
Headline
Committee Chairman Richard Neal, D-Mass., and Ranking Member Kevin Brady, R-Texas, said they are committed to working on bipartisan reforms to lower drug…